Many methods used in fragment-based drug discovery pose real challenges — SPR often struggles to detect true hits due to fragments’ small mass, DSF can have high rates of false positives, and NMR equipment is expensive to set up and maintain. These challenges make it difficult to find the best fragment hits quickly and cost-effectively.
Join this webinar to learn how Dianthus with Spectral Shift technology — a mass-independent, in-solution screening platform — overcomes these hurdles and makes fragment screening faster and less expensive while providing trustworthy hit rates and biophysical affinity measurements.
In this case study, you’ll see how Dianthus with Spectral Shift technology was used to screen a fragment library against a DNA-binding protein and:
- Find hits in the micromolar affinity range with a hit rate 75% lower than DSF
- Complete primary and affinity screenings using small amounts of target and fragments
- Screen over 1,600 compounds in just a few days with a fully automated setup
